

Supplementary Figure 5. No defect in HSPC homing efficiency after 6OHDA or cisplatin treatment. (**a**) Experimental design to determine the efficiency of HSC homing to the BM of saline- or cisplatin-treated mice. (**b**) Percentage of donor CFU-C (left) or LSKF cells (right) detected in the BM of saline- (black) or cisplatin- (grey) treated mice 24h after lethal irradiation (1200 rads) and injection of $5x10^6$ (CFU-C) or $10x10^6$ (LSKF) donor BMNC (n = 4–7). (**c**) Percentage of $CD45.1^+$ cells in peripheral blood of $CD45.2^+$ recipient mice 16 weeks after competitive transplant as depicted in a. (**d**) Percentage of donor CFU-C (left) or LSKF cells (right) detected in the BM of saline- (blue) or 6OHDA- (red) mice 24h after lethal irradiation (1200 rads) and injection of $5x10^6$ (CFU-C) or $10x10^6$ (LSKF) donor BMNC (n = 4–6). (**e**) Percentage of $CD45.1^+$ cells in peripheral blood of $CD45.2^+$ recipient mice 16 weeks after competitive transplant as depicted in a but with saline- or 6OHDA-treated mice. (**f**) Experimental design to determine whether sublethal irradiation of 6OHDA-treated mice also results in reduced BM recovery. (**g-i**) Number of BMNC (**g**), CFU-C (**h**), and LSKF cells (**i**) per femur in saline or 6OHDA-treated mice 12 days after sublethal irradiation (n = 3–7).